Our reasoning for this is that we have previously demonstrated that IL1β has opposing effects on tumour growth in the bone compared with soft tissue [13] and that these differences in pro/anti-tumour effects are driven by differential, site-specific, immunological responses [13]. The gene discussed is IL1B; the disease is neoplasm.